Survival Impact of Second-Line Immune Checkpoint Inhibitors in Older Patients With Advanced Squamous-Cell NSCLC: Post Hoc Analysis of the CAPITAL Study

INTRODUCTION: In the CAPITAL study, a randomized phase 3 study, wherein carboplatin plus nab-paclitaxel treatment was compared with docetaxel treatment for older patients with squamous-cell lung cancer, the former became the new standard of care for such patients. Our study aimed to evaluate whether...

Descripción completa

Detalles Bibliográficos
Autores principales: Kogure, Yoshihito, Kada, Akiko, Hashimoto, Hiroya, Atagi, Shinji, Takiguchi, Yuichi, Saka, Hideo, Ebi, Noriyuki, Inoue, Akira, Kurata, Takayasu, Fujita, Yuka, Nishii, Yoichi, Itani, Hidetoshi, Endo, Takeo, Saito, Akiko M., Shibayama, Takuo, Yamamoto, Nobuyuki, Gemma, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250914/
https://www.ncbi.nlm.nih.gov/pubmed/37304652
http://dx.doi.org/10.1016/j.jtocrr.2023.100514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250914/
https://www.ncbi.nlm.nih.gov/pubmed/37304652
http://dx.doi.org/10.1016/j.jtocrr.2023.100514

Ejemplares similares